MPM BioImpact adds three China-origin drug programs to K2 Therapeutics portfolio
read at Endpoints ↗DealPositive
MPM BioImpact, a biotech investment firm, is intensifying its "best of both worlds" approach by bringing drug candidates that originated in China to a broader market.
Over the past year its portfolio company K2 Therapeutics has gathered three separate drug programs that were discovered or developed in China, adding to the firm’s pipeline.
The move reflects MPM's confidence that Chinese-origin assets can succeed globally and signals continued focus on cross-border biotech collaborations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “MPM has collected three China drugs for its ‘best of both worlds’ strategy”
read at Endpoints ↗98 words · retrieved Apr 29
comments(0)
5-min edit window · permanent after that